Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance

GSK Says Health Canada Accepted Jemperli For Accelerated Review In Genetic Subtype Of Locally Advanced Rectal Cancer

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

Managing Service Providers Including CRO and CMOs Oversight to Comply with ICH GCP R3 Scheduled for October 14–15, 2027

A two-day online training course on managing Contract Research Organisations (CROs) and Contract Manufacturing Organisations (CMOs) under ICH GCP R3 guidelines will be delivered by IPI Academy on October 14-15, 2027. The course addresses sponsor oversight, vendor selection, risk-based management, and regulatory compliance expectations for pharmaceutical and biotech organisations.

8-K filing — SCYNEXIS INC (SCYX)

Filed: 2026-09-22 AccNo: 0001178253-26-000035 Size: 201 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9

Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served